Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$7.94 USD
-0.18 (-2.22%)
Updated Mar 27, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Actinium Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 1 | 1 | 0 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 1 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 35 | 26 | 22 | 22 |
Income After Depreciation & Amortization | 0 | -34 | -25 | -22 | -22 |
Non-Operating Income | NA | 1 | 0 | 0 | 0 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -33 | -25 | -22 | -22 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -33 | -25 | -22 | -22 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -33 | -25 | -22 | -22 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -33 | -24 | -22 | -22 |
Depreciation & Amortization (Cash Flow) | NA | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -34 | -25 | -22 | -22 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 24.14 | NA | 12.13 | NA |
Diluted EPS Before Non-Recurring Items | NA | -1.37 | NA | -1.83 | NA |
Diluted Net EPS (GAAP) | NA | -1.37 | -1.20 | -1.83 | -4.50 |
Fiscal Year end for Actinium Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 14.35 | 15.64 | 11.59 | 11.29 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -14.35 | -15.64 | -11.59 | -11.29 |
Non-Operating Income | NA | 1.08 | 0.46 | 0.55 | 0.64 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -13.28 | -15.18 | -11.04 | -10.65 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -13.28 | -15.18 | -11.04 | -10.65 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -13.28 | -15.18 | -11.04 | -10.65 |
Earnings Per Share Data | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 |
---|---|---|---|---|---|
Average Shares | NA | 27.06 | 26.22 | 25.70 | 25.15 |
Diluted EPS Before Non-Recurring Items | NA | -0.49 | -0.58 | -0.43 | -0.42 |
Diluted Net EPS (GAAP) | NA | -0.49 | -0.58 | -0.43 | -0.43 |